Lavino Francesco Maria 4

4 · Nabriva Therapeutics plc · Filed Feb 4, 2019

Form 4

Period: 2019-01-31

Chief Commercial Officer

Transactions

Award
Restricted Stock Units
2019-01-31+52,500→ 52,500 total
Exp: 2023-01-31→ Ordinary Shares (52,500 underlying)
Award
Stock Options
2019-01-31+138,200→ 138,200 total
Exp: 2029-01-31→ Ordinary Shares (138,200 underlying)

Footnotes (4)

[F1]The exercise price is $1.90 per share.
[F2]This option was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
[F3]The restricted stock unit shall convert into ordinary shares on a one-for-one basis upom vesting of the units.
[F4]The restricted stock unit award was granted on January 31, 2019. Vesting began on January 31, 2019 and ends on January 31, 2023. Twenty-five percent (25%) of the restricted stock unit award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the restricted stock unit award will vest on a monthly pro-rata basis over the remaining vesting period.

Documents

1 file